Journal of clinical virology plus最新文献_第4页

Genomic analysis of SARS-CoV-2 sequences obtained in Tanzania during the pandemic 大流行期间在坦桑尼亚获得的SARS-CoV-2序列的基因组分析

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2025-06-01 Epub Date: 2025-04-15 DOI: 10.1016/j.jcvp.2025.100212

Nicholaus P. Mnyambwa , Jinxin Gao , Alex Magesa , Edina Mgimba , Swaminathan Mahesh , Pawan Angra , Juma Kisuse , Clara Lubinza , Lawrence Mapunda , Aman Wilfred , Godfather Kimaro , George P. Judicate , Ambele Eliah , Augustino Msanga , Senkoro Mbazi , Esther Ngadaya , Mukurasi Kokuhabwa , Jackson P. Mushumbusi , Medard Beyanga , Wangeci Gatei , Sayoki Mfinanga

Background

Genomic sequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from Tanzania remain scarce in GISAID, thus hindering our understanding of how the pandemic evolved in the country.

Methods

We performed whole genome sequencing on SARS-CoV-2 samples collected between March 2021 and December 2022 to characterize the virus in Tanzania. Nasal and oropharyngeal swabs were collected from patients seeking health care, incoming travelers as well as from outgoing travelers undergoing pre-travel COVID-19 testing (required for flight boarding). Sample collection, and testing were coordinated by the National Public Health Laboratory.

Results

Among 515 samples, 260 (50.49 %) were from outgoing travelers, 227 (44.08 %) Covid-19 suspects seeking care, and 28 (5.44 %) incoming travelers identified at the airport. The majority of the samples came from Dar es Salaam (n = 380, 73.7 %), the country's largest city and the main port of entry. We identified 74 Pango lineages from all the samples, with Omicron 430 (83.50 %) and Delta 79 (15 %) variants being predominant. From the 380 Dar es Salaam samples, 67 Pango lineages were identified, showing both overlapping and unique lineages in each sample type.

Conclusion

Our findings reveal a dynamic circulation of SARS-CoV-2 variants over time, with Delta predominantly observed in 2021 and Omicron in 2022 in Tanzania. The temporal prevalence of the identified lineages was consistent with the global epidemiology of the virus. Sustained and expanded genomic surveillance is recommended to track and respond effectively to emerging variants.

来自坦桑尼亚的严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）的基因组序列在GISAID中仍然很少，因此阻碍了我们对该国大流行如何演变的理解。方法对2021年3月至2022年12月在坦桑尼亚采集的SARS-CoV-2样本进行全基因组测序，以表征该病毒。从寻求医疗保健的患者、入境旅客以及接受旅行前COVID-19检测（登机所需）的出境旅客中收集鼻和口咽拭子。样本收集和检测由国家公共卫生实验室协调。结果515份样本中，260份（50.49%）来自出境旅客，227份（44.08%）来自寻求治疗的Covid-19疑似病例，28份（5.44%）来自机场发现的入境旅客。大多数样本来自该国最大城市和主要入境口岸达累斯萨拉姆（n = 380, 73.7%）。我们从所有样本中鉴定出74个Pango谱系，其中Omicron 430（83.50%）和Delta 79（15%）变体占主导地位。从达累斯萨拉姆的380个样本中，鉴定出67个Pango血统，每种样本类型都显示出重叠和独特的血统。我们的研究结果揭示了SARS-CoV-2变异随时间的动态循环，在坦桑尼亚主要观察到Delta变异在2021年，Omicron变异在2022年。所确定谱系的时间流行率与病毒的全球流行病学一致。建议持续和扩大基因组监测，以跟踪和有效应对新出现的变异。

{"title":"Genomic analysis of SARS-CoV-2 sequences obtained in Tanzania during the pandemic","authors":"Nicholaus P. Mnyambwa , Jinxin Gao , Alex Magesa , Edina Mgimba , Swaminathan Mahesh , Pawan Angra , Juma Kisuse , Clara Lubinza , Lawrence Mapunda , Aman Wilfred , Godfather Kimaro , George P. Judicate , Ambele Eliah , Augustino Msanga , Senkoro Mbazi , Esther Ngadaya , Mukurasi Kokuhabwa , Jackson P. Mushumbusi , Medard Beyanga , Wangeci Gatei , Sayoki Mfinanga","doi":"10.1016/j.jcvp.2025.100212","DOIUrl":"10.1016/j.jcvp.2025.100212","url":null,"abstract":"<div><h3>Background</h3><div>Genomic sequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from Tanzania remain scarce in GISAID, thus hindering our understanding of how the pandemic evolved in the country.</div></div><div><h3>Methods</h3><div>We performed whole genome sequencing on SARS-CoV-2 samples collected between March 2021 and December 2022 to characterize the virus in Tanzania. Nasal and oropharyngeal swabs were collected from patients seeking health care, incoming travelers as well as from outgoing travelers undergoing pre-travel COVID-19 testing (required for flight boarding). Sample collection, and testing were coordinated by the National Public Health Laboratory.</div></div><div><h3>Results</h3><div>Among 515 samples, 260 (50.49 %) were from outgoing travelers, 227 (44.08 %) Covid-19 suspects seeking care, and 28 (5.44 %) incoming travelers identified at the airport. The majority of the samples came from Dar es Salaam (<em>n</em> = 380, 73.7 %), the country's largest city and the main port of entry. We identified 74 Pango lineages from all the samples, with Omicron 430 (83.50 %) and Delta 79 (15 %) variants being predominant. From the 380 Dar es Salaam samples, 67 Pango lineages were identified, showing both overlapping and unique lineages in each sample type.</div></div><div><h3>Conclusion</h3><div>Our findings reveal a dynamic circulation of SARS-CoV-2 variants over time, with Delta predominantly observed in 2021 and Omicron in 2022 in Tanzania. The temporal prevalence of the identified lineages was consistent with the global epidemiology of the virus. Sustained and expanded genomic surveillance is recommended to track and respond effectively to emerging variants.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 2","pages":"Article 100212"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143864808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Urgent attention for health care services preparedness to address rising human metapneumovirus (HMPV) cases 紧急关注卫生保健服务准备，以应对不断上升的人偏肺病毒（HMPV）病例

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2025-06-01 Epub Date: 2025-03-24 DOI: 10.1016/j.jcvp.2025.100209

Md. Salman Sohel , Safayet Jamil , Md. Naimur Rahman

引用次数: 0

Hepatitis B and C infection in tuberculosis patients in the Hauts Bassins region of Burkina Faso, West Africa 西非布基纳法索上盆地地区肺结核患者的乙型和丙型肝炎感染

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2025-06-01 Epub Date: 2025-04-14 DOI: 10.1016/j.jcvp.2025.100211

Armel Moumouni Sanou , Abdoulaye Dera , Jeoffray Diendere , Nina Mathuola Geneviève Ouattara , Eric Kyelem , Arhouna Siguina Traore , Arouna Dao , Arielle Sandra Bettina Badiel , Ina Marie Angèle Traore , Michel Kiréopori.B Gomgnimbou , Isidore Bonkoungou , Gautier Henri Ouedraogo

Tuberculosis (TB) and viral hepatitis B and C represent significant public health concerns. Co-infection with TB and hepatitis B and/or C results in significant complications, including suboptimal treatment outcomes in TB and the development of hepatitis induced by anti-TB drugs. At present, no data on these co-infections are available for Burkina Faso. This study investigates the epidemiology of these co-infections in TB patients in the Hauts-Bassins region of Burkina Faso. A cross-sectional analytical study was conducted in health facilities involved in the management of TB in the Hauts-Bassins region of Burkina Faso from October 2023 to June 2024. For each consenting TB patient, data were collected. A blood sample was obtained and analyzed for a range of infection markers (HBsAg, HBV DNA, anti-HCV antibodies, and HCV RNA) and liver enzymes (ALT and γ-GT). A total of 259 TB patients were included in the study. The mean age of the participants was 39.7 ± 15.9 years. The overall prevalence of HBsAg was 10.03 % and 3.8 % for anti-HCV. Among the HBsAg-positive samples, HBV DNA was detected in all cases, with 68.2 % exhibiting a viral load exceeding 20,000 IU/mL. Elevated ALT was observed in 19.2 % of TB/HBsAg patients and in 30.0 % of TB/anti-HCV. About γ-GT, an elavated result was observed in 46.1 % of TB/HBsAg patients and 40.0 % of TB/anti-HCV patients. The results demonstrated a high prevalence of hepatitis B and intermediate exposure to HCV in TB patients. It is thus recommended that routine screening for these diseases be considered in TB patients.

结核病（TB）和病毒性乙型和丙型肝炎是重大的公共卫生问题。结核病与乙型和/或丙型肝炎合并感染会导致严重并发症，包括结核病治疗效果欠佳和抗结核药物诱发肝炎。目前，布基纳法索没有关于这些合并感染的数据。本研究调查了布基纳法索上盆地地区结核病患者中这些合并感染的流行病学。从2023年10月至2024年6月，在布基纳法索上盆地地区参与结核病管理的卫生设施中进行了一项横断面分析研究。对每个同意结核病的患者收集数据。采集血样并分析一系列感染标志物（HBsAg、HBV DNA、抗HCV抗体和HCV RNA）和肝酶（ALT和γ-GT）。该研究共纳入了259名结核病患者。参与者平均年龄为39.7±15.9岁。总体HBsAg患病率为10.03%，抗hcv患病率为3.8%。在hbsag阳性样本中，所有病例均检测到HBV DNA，其中68.2%的病毒载量超过20,000 IU/mL。在19.2%的TB/HBsAg患者和30.0%的TB/anti-HCV患者中观察到ALT升高。关于γ-GT， 46.1%的TB/HBsAg患者和40.0%的TB/anti-HCV患者的γ-GT升高。结果表明，在结核病患者中，乙型肝炎患病率高，丙型肝炎暴露程度中等。因此，建议在结核病患者中考虑对这些疾病进行常规筛查。

{"title":"Hepatitis B and C infection in tuberculosis patients in the Hauts Bassins region of Burkina Faso, West Africa","authors":"Armel Moumouni Sanou , Abdoulaye Dera , Jeoffray Diendere , Nina Mathuola Geneviève Ouattara , Eric Kyelem , Arhouna Siguina Traore , Arouna Dao , Arielle Sandra Bettina Badiel , Ina Marie Angèle Traore , Michel Kiréopori.B Gomgnimbou , Isidore Bonkoungou , Gautier Henri Ouedraogo","doi":"10.1016/j.jcvp.2025.100211","DOIUrl":"10.1016/j.jcvp.2025.100211","url":null,"abstract":"<div><div>Tuberculosis (TB) and viral hepatitis B and C represent significant public health concerns. Co-infection with TB and hepatitis B and/or C results in significant complications, including suboptimal treatment outcomes in TB and the development of hepatitis induced by anti-TB drugs. At present, no data on these co-infections are available for Burkina Faso. This study investigates the epidemiology of these co-infections in TB patients in the Hauts-Bassins region of Burkina Faso. A cross-sectional analytical study was conducted in health facilities involved in the management of TB in the Hauts-Bassins region of Burkina Faso from October 2023 to June 2024. For each consenting TB patient, data were collected. A blood sample was obtained and analyzed for a range of infection markers (HBsAg, HBV DNA, anti-HCV antibodies, and HCV RNA) and liver enzymes (ALT and γ-GT). A total of 259 TB patients were included in the study. The mean age of the participants was 39.7 ± 15.9 years. The overall prevalence of HBsAg was 10.03 % and 3.8 % for anti-HCV. Among the HBsAg-positive samples, HBV DNA was detected in all cases, with 68.2 % exhibiting a viral load exceeding 20,000 IU/mL. Elevated ALT was observed in 19.2 % of TB/HBsAg patients and in 30.0 % of TB/anti-HCV. About γ-GT, an elavated result was observed in 46.1 % of TB/HBsAg patients and 40.0 % of TB/anti-HCV patients. The results demonstrated a high prevalence of hepatitis B and intermediate exposure to HCV in TB patients. It is thus recommended that routine screening for these diseases be considered in TB patients.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 2","pages":"Article 100211"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143848190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient characteristics, treatment patterns, and clinical outcomes of remdesivir in hospitalized COVID-19 patients with diabetes mellitus on insulin: A large-scale data analysis using a Japanese claims database 患者特征、治疗模式和瑞德西韦在住院的COVID-19合并胰岛素治疗的糖尿病患者中的临床结局：使用日本索赔数据库的大规模数据分析

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2025-06-01 Epub Date: 2025-05-17 DOI: 10.1016/j.jcvp.2025.100216

Manami Yoshida , Nao Taguchi , Yi Piao , Rikisha Gupta , Jami Peters , Mazin Abdelghany , Mel Chiang , Chen-Yu Wang , Mark Berry , Hiroshi Yotsuyanagi

Aim

To describe treatment patterns and clinical outcomes in Japanese patients with diabetes mellitus (DM) hospitalized for coronavirus disease-2019 (COVID-19) treated with remdesivir (RDV).

Methods

We included data from patients aged ≥ 18 years with DM on insulin, hospitalized for moderate to severe COVID-19, and who received ≥ 1 dose of RDV between October 2021 and September 2022, using a Japanese medical claims database. All-cause mortality, progression to severe COVID-19, and hospital discharge/recovery status were evaluated up to 56 days from the index date defined as RDV initiation.

Results

The analysis included 502 patients. The mean (SD) age at index was 74.4 (12.5) years. Median (Q1–Q3) time to RDV initiation was 2.0 (1.0–3.0) days from hospital admission; median treatment duration was 5.0 (3.0–5.0) days. At index date, 36.85 % of patients had moderate I disease (hospitalized without oxygen support), 58.96 % had moderate II disease (non-invasive positive pressure ventilation, low/high-flow oxygen), and 4.18 % had severe disease (ICU admission, mechanical ventilation, or extracorporeal membrane oxygenation). Proportion of patients with all-cause mortality was 11.16 % (95 % CI, 8.54–14.24) and 13.15 % (10.32–16.42) by 28 and 56 days. At 28 days, 12.35 % (9.60–15.55) of patients had disease progression, and 68.13 % (63.85–72.19) had recovery.

Conclusion

Most patients were elderly and required oxygen support when initiating RDV. The majority of patients received RDV within 3 days of hospitalization and recovered by 28 days. The study provides insight into outcomes in Japanese COVID-19 patients with DM treated with RDV in inpatient settings.

目的探讨瑞德西韦（RDV）治疗日本因冠状病毒病-2019 （COVID-19）住院的糖尿病（DM）患者的治疗模式和临床结果。方法：我们使用日本医疗索赔数据库，纳入了年龄≥18岁、接受胰岛素治疗的糖尿病患者、因中重度COVID-19住院且在2021年10月至2022年9月期间接受了≥1剂量RDV治疗的患者的数据。从定义为RDV开始的指标日期起56天内评估全因死亡率、进展到严重COVID-19和出院/康复状况。结果共纳入502例患者。平均（SD）年龄为74.4（12.5）岁。从入院到RDV发生的中位时间（Q1-Q3）为2.0（1.0-3.0）天；中位治疗时间为5.0（3.0-5.0）天。截至指标日，36.85%的患者为中度I型疾病（住院无氧支持），58.96%的患者为中度II型疾病（无创正压通气，低/高流量氧气），4.18%的患者为重度疾病（ICU入院，机械通气或体外膜氧合）。28天和56天全因死亡率分别为11.16% （95% CI, 8.54 ~ 14.24）和13.15%（10.32 ~ 16.42）。28 d时，12.35%（9.60 ~ 15.55）的患者出现疾病进展，68.13%（63.85 ~ 72.19）的患者恢复。结论患者多为老年患者，启动RDV时需吸氧支持。大多数患者在住院3天内接受RDV治疗，28天康复。该研究为在住院环境中接受RDV治疗的日本COVID-19 DM患者的结果提供了见解。

{"title":"Patient characteristics, treatment patterns, and clinical outcomes of remdesivir in hospitalized COVID-19 patients with diabetes mellitus on insulin: A large-scale data analysis using a Japanese claims database","authors":"Manami Yoshida , Nao Taguchi , Yi Piao , Rikisha Gupta , Jami Peters , Mazin Abdelghany , Mel Chiang , Chen-Yu Wang , Mark Berry , Hiroshi Yotsuyanagi","doi":"10.1016/j.jcvp.2025.100216","DOIUrl":"10.1016/j.jcvp.2025.100216","url":null,"abstract":"<div><h3>Aim</h3><div>To describe treatment patterns and clinical outcomes in Japanese patients with diabetes mellitus (DM) hospitalized for coronavirus disease-2019 (COVID-19) treated with remdesivir (RDV).</div></div><div><h3>Methods</h3><div>We included data from patients aged ≥ 18 years with DM on insulin, hospitalized for moderate to severe COVID-19, and who received ≥ 1 dose of RDV between October 2021 and September 2022, using a Japanese medical claims database. All-cause mortality, progression to severe COVID-19, and hospital discharge/recovery status were evaluated up to 56 days from the index date defined as RDV initiation.</div></div><div><h3>Results</h3><div>The analysis included 502 patients. The mean (SD) age at index was 74.4 (12.5) years. Median (Q1–Q3) time to RDV initiation was 2.0 (1.0–3.0) days from hospital admission; median treatment duration was 5.0 (3.0–5.0) days. At index date, 36.85 % of patients had moderate I disease (hospitalized without oxygen support), 58.96 % had moderate II disease (non-invasive positive pressure ventilation, low/high-flow oxygen), and 4.18 % had severe disease (ICU admission, mechanical ventilation, or extracorporeal membrane oxygenation). Proportion of patients with all-cause mortality was 11.16 % (95 % CI, 8.54–14.24) and 13.15 % (10.32–16.42) by 28 and 56 days. At 28 days, 12.35 % (9.60–15.55) of patients had disease progression, and 68.13 % (63.85–72.19) had recovery.</div></div><div><h3>Conclusion</h3><div>Most patients were elderly and required oxygen support when initiating RDV. The majority of patients received RDV within 3 days of hospitalization and recovered by 28 days. The study provides insight into outcomes in Japanese COVID-19 patients with DM treated with RDV in inpatient settings.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 2","pages":"Article 100216"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Elevated levels of platelet-activating factor and syndecan-1 in severe dengue infections 重度登革热感染中血小板活化因子和syndecan-1水平升高

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2025-06-01 Epub Date: 2025-04-14 DOI: 10.1016/j.jcvp.2025.100213

Sri Masyeni , I Made Wisnu Wardhana , Pande Ayu Nayakasih Permatananda , Arya Giri Prebawa , Saraswati Laksmi Dewi , Erni Juwita Nelwan

Background

Severe dengue is a serious infection associated with cytokine storms.

Objectives: This study investigated the roles of platelet-activating factor (PAF), syndecan-1, and matrix metalloprotein-9 (MMP-9) in dengue severity.

Study design

Blood samples were collected to confirm the diagnosis of dengue infection, and to assess disease severity. Tests performed included non-structural protein 1 dengue test, immunoglobulin G/immunoglobulin M dengue tests, real-time polymerase chain reaction, enzyme-linked immunosorbent assay, and a complete blood count. Patients with dengue infection were classified as having dengue fever or dengue hemorrhagic fever.

Results

The median levels of PAF, syndecan-1, and MMP-9 in all patients were 73.27 (14.2–769.1) pg/mL, 5.4 (2–64.3) pg/mL, and 197.8 (95.3–962.8) pg/mL, respectively. The levels of all three biomarkers were significantly higher in the dengue hemorrhagic fever and secondary infection groups; with p values < 0.001. Multivariate analysis revealed that PAF and syndecan-1 levels significantly correlated with the severity of dengue infection. Syndecan-1 had the strongest correlation, with a correlation coefficient of 0.43, whereas PAF had a correlation coefficient of 0.30.

Conclusions

PAF and syndecan-1 were both independently associated with severe dengue; however, further longitudinal studies are required to validate their predictive potential.

背景：重症登革热是一种与细胞因子风暴相关的严重感染。目的：本研究探讨血小板活化因子（PAF）、syndecan-1和基质金属蛋白9 （MMP-9）在登革热严重程度中的作用。研究设计采集血液样本以确认登革热感染的诊断，并评估疾病严重程度。进行的检测包括非结构蛋白1登革热试验、免疫球蛋白G/免疫球蛋白M登革热试验、实时聚合酶链反应、酶联免疫吸附试验和全血细胞计数。登革热感染患者分为登革热或登革出血热。结果所有患者PAF、syndecan-1和MMP-9的中位水平分别为73.27 (14.2-769.1)pg/mL、5.4 (2-64.3)pg/mL和197.8 (95.3-962.8)pg/mL。在登革出血热和继发感染组中，这三种生物标志物的水平均显著较高；p值<；0.001. 多因素分析显示，PAF和syndecan-1水平与登革热感染严重程度显著相关。Syndecan-1的相关性最强，相关系数为0.43，PAF的相关系数为0.30。结论spaf和syndecan-1均与重症登革热独立相关；然而，需要进一步的纵向研究来验证其预测潜力。

{"title":"Elevated levels of platelet-activating factor and syndecan-1 in severe dengue infections","authors":"Sri Masyeni , I Made Wisnu Wardhana , Pande Ayu Nayakasih Permatananda , Arya Giri Prebawa , Saraswati Laksmi Dewi , Erni Juwita Nelwan","doi":"10.1016/j.jcvp.2025.100213","DOIUrl":"10.1016/j.jcvp.2025.100213","url":null,"abstract":"<div><h3>Background</h3><div>Severe dengue is a serious infection associated with cytokine storms.</div><div>Objectives: This study investigated the roles of platelet-activating factor (PAF), syndecan-1, and matrix metalloprotein-9 (MMP-9) in dengue severity.</div></div><div><h3>Study design</h3><div>Blood samples were collected to confirm the diagnosis of dengue infection, and to assess disease severity. Tests performed included non-structural protein 1 dengue test, immunoglobulin G/immunoglobulin M dengue tests, real-time polymerase chain reaction, enzyme-linked immunosorbent assay, and a complete blood count. Patients with dengue infection were classified as having dengue fever or dengue hemorrhagic fever.</div></div><div><h3>Results</h3><div>The median levels of PAF, syndecan-1, and MMP-9 in all patients were 73.27 (14.2–769.1) pg/mL, 5.4 (2–64.3) pg/mL, and 197.8 (95.3–962.8) pg/mL, respectively. The levels of all three biomarkers were significantly higher in the dengue hemorrhagic fever and secondary infection groups; with <em>p</em> values < 0.001. Multivariate analysis revealed that PAF and syndecan-1 levels significantly correlated with the severity of dengue infection. Syndecan-1 had the strongest correlation, with a correlation coefficient of 0.43, whereas PAF had a correlation coefficient of 0.30.</div></div><div><h3>Conclusions</h3><div>PAF and syndecan-1 were both independently associated with severe dengue; however, further longitudinal studies are required to validate their predictive potential.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 2","pages":"Article 100213"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comprehensive HPV genotyping in Fars, Iran: Molecular epidemiology and implications for prevention 伊朗法尔斯的全面HPV基因分型：分子流行病学和预防意义

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2025-06-01 Epub Date: 2025-05-16 DOI: 10.1016/j.jcvp.2025.100214

Amirreza Radfar , Neda Pirbonyeh , Afagh Moattari

Background

Human papillomavirus (HPV) is the most prevalent sexually transmitted infection, with high-risk genotypes contributing to cervical and other cancers. While HPV epidemiology has been studied in Iran, comprehensive genotype distribution data remain limited for Fars province. This study examines HPV prevalence and genotype distribution to inform regional prevention strategies.

Methods

This cross-sectional study analyzed 616 samples collected from a clinical laboratory between 2021 and 2024. HPV DNA was detected using nested PCR, and genotyping was performed via reverse hybridization. Associations between HPV status, risk classification, gender, and sample collection method were statistically assessed.

Results

Overall, 56.3 % of individuals tested positive for HPV. High-risk HPV was detected in 56.6 % of positive cases, with HPV-16 (29.6 %) and HPV-18 (6.8 %) being the most common oncogenic types. Low-risk HPV-6 (35.0 %) and HPV-11 (17.1 %) were also prevalent. No significant associations were found between HPV status and age (p = 0.346), gender (p = 0.998), or sample collection method (p = 0.998).

Conclusion

The predominance of vaccine-covered HPV types underscores the need for expanded screening and targeted prevention programs in Fars province. Although demographic factors were not significantly associated with HPV status, the high burden of high-risk types necessitates stronger regional public health interventions. These findings contribute valuable epidemiological data to enhance HPV control measures and optimize vaccination policies.

人类乳头瘤病毒（HPV）是最普遍的性传播感染，具有高危基因型，可导致宫颈癌和其他癌症。虽然在伊朗研究了HPV流行病学，但法尔斯省的综合基因型分布数据仍然有限。本研究检查HPV患病率和基因型分布，为区域预防策略提供信息。方法本横断面研究分析了2021年至2024年从临床实验室收集的616份样本。采用巢式PCR检测HPV DNA，并通过反向杂交进行基因分型。统计评估HPV状态、风险分类、性别和样本收集方法之间的关系。结果总体上，56.3%的人HPV检测呈阳性。在56.6%的阳性病例中检测到高危HPV，其中HPV-16（29.6%）和HPV-18（6.8%）是最常见的致癌类型。低危HPV-6（35.0%）和HPV-11（17.1%）也普遍存在。HPV状态与年龄（p = 0.346）、性别（p = 0.998）或样本采集方法（p = 0.998）无显著相关性。结论法尔斯省疫苗覆盖HPV类型的优势强调了扩大筛查和有针对性的预防规划的必要性。虽然人口因素与人乳头瘤病毒状况没有显著相关性，但高风险类型的高负担需要加强区域公共卫生干预。这些发现为加强HPV控制措施和优化疫苗接种政策提供了宝贵的流行病学数据。

{"title":"Comprehensive HPV genotyping in Fars, Iran: Molecular epidemiology and implications for prevention","authors":"Amirreza Radfar , Neda Pirbonyeh , Afagh Moattari","doi":"10.1016/j.jcvp.2025.100214","DOIUrl":"10.1016/j.jcvp.2025.100214","url":null,"abstract":"<div><h3>Background</h3><div>Human papillomavirus (HPV) is the most prevalent sexually transmitted infection, with high-risk genotypes contributing to cervical and other cancers. While HPV epidemiology has been studied in Iran, comprehensive genotype distribution data remain limited for Fars province. This study examines HPV prevalence and genotype distribution to inform regional prevention strategies.</div></div><div><h3>Methods</h3><div>This cross-sectional study analyzed 616 samples collected from a clinical laboratory between 2021 and 2024. HPV DNA was detected using nested PCR, and genotyping was performed via reverse hybridization. Associations between HPV status, risk classification, gender, and sample collection method were statistically assessed.</div></div><div><h3>Results</h3><div>Overall, 56.3 % of individuals tested positive for HPV. High-risk HPV was detected in 56.6 % of positive cases, with HPV-16 (29.6 %) and HPV-18 (6.8 %) being the most common oncogenic types. Low-risk HPV-6 (35.0 %) and HPV-11 (17.1 %) were also prevalent. No significant associations were found between HPV status and age (<em>p</em> = 0.346), gender (<em>p</em> = 0.998), or sample collection method (<em>p</em> = 0.998).</div></div><div><h3>Conclusion</h3><div>The predominance of vaccine-covered HPV types underscores the need for expanded screening and targeted prevention programs in Fars province. Although demographic factors were not significantly associated with HPV status, the high burden of high-risk types necessitates stronger regional public health interventions. These findings contribute valuable epidemiological data to enhance HPV control measures and optimize vaccination policies.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 2","pages":"Article 100214"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144114943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SARS-CoV-2 antibody response and serum neutralizing capacity of early unvaccinated COVID-19 patients in the Philippines 菲律宾早期未接种COVID-19患者的SARS-CoV-2抗体反应和血清中和能力

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2025-06-01 Epub Date: 2025-05-22 DOI: 10.1016/j.jcvp.2025.100217

Eloina Faye S. Gampoy , Gielenny M. Salem , Jedhan U. Galula , Fresthel Monica M. Climacosa , Leslie Michelle M. Dalmacio , Day-Yu Chao

Objectives

The immune response to SARS-CoV-2 infection, particularly the dynamics of antigen-specific and isotype-specific antibodies, is critical for understanding disease progression and outcomes. This study characterizes the antibody profiles and serum neutralizing capacity as well as its relationship with disease severity among COVID-19 patients from the Philippines, prior to the national COVID-19 vaccination rollout.

Methods

A total of 177 serum samples from 67 hospitalized patients with RT-PCR-confirmed COVID-19 were analyzed during the first wave of the pandemic between October 2020 to April 2021. Various antibody isotypes (IgG, IgM, and IgA) against SARS-CoV-2 S1, S2, RBD, and N proteins, as well as IgG antibodies against human ACE2, were quantified by enzyme-linked immunosorbent assay (ELISA). Serum neutralizing capacity was assessed by ACE2-RBD binding inhibition assay and pseudovirus neutralization assays. The relationship of the binding antibodies with various clinical parameters was also determined.

Results

IgG, IgM, and IgA antibody responses were associated with disease severity within two weeks of symptom onset. Notably, IgM responses positively correlated with elevated inflammatory markers, including ferritin and C-reactive protein, while IgM-N predicted in-hospital mortality. However, patient sera lacked neutralizing activity against the SARS-CoV-2 Wuhan strain. While the anti-ACE2 IgG antibodies were detected, their presence was not associated with disease severity or inflammatory responses.

Conclusions

These findings suggest that while binding antibodies are prevalent early in infection among COVID-19 patients early in the pandemic, serum neutralizing capacity remains low in the absence of vaccination. The clinical significance of detectable anit-ACE2 antibodies in COVID-19 warrants further investigation.

对SARS-CoV-2感染的免疫反应，特别是抗原特异性和同型特异性抗体的动态，对于了解疾病进展和结局至关重要。本研究描述了在全国COVID-19疫苗接种之前，菲律宾COVID-19患者的抗体谱和血清中和能力及其与疾病严重程度的关系。方法对2020年10月至2021年4月第一波疫情期间67例经rt - pcr确诊的住院患者177份血清样本进行分析。采用酶联免疫吸附试验（ELISA）定量检测针对SARS-CoV-2 S1、S2、RBD和N蛋白的各种抗体同型（IgG、IgM和IgA）以及针对人ACE2的IgG抗体。采用ACE2-RBD结合抑制试验和假病毒中和试验评估血清中和能力。结合抗体与各种临床参数的关系也被确定。结果igg、IgM和IgA抗体反应与症状出现两周内疾病严重程度相关。值得注意的是，IgM反应与炎症标志物升高呈正相关，包括铁蛋白和c反应蛋白，而IgM- n预测住院死亡率。然而，患者血清缺乏对SARS-CoV-2武汉株的中和活性。虽然检测到抗ace2 IgG抗体，但它们的存在与疾病严重程度或炎症反应无关。结论这些结果表明，尽管结合抗体在大流行早期COVID-19患者感染早期普遍存在，但在没有接种疫苗的情况下，血清中和能力仍然较低。抗ace2抗体检测在COVID-19中的临床意义有待进一步研究。

{"title":"SARS-CoV-2 antibody response and serum neutralizing capacity of early unvaccinated COVID-19 patients in the Philippines","authors":"Eloina Faye S. Gampoy , Gielenny M. Salem , Jedhan U. Galula , Fresthel Monica M. Climacosa , Leslie Michelle M. Dalmacio , Day-Yu Chao","doi":"10.1016/j.jcvp.2025.100217","DOIUrl":"10.1016/j.jcvp.2025.100217","url":null,"abstract":"<div><h3>Objectives</h3><div>The immune response to SARS-CoV-2 infection, particularly the dynamics of antigen-specific and isotype-specific antibodies, is critical for understanding disease progression and outcomes. This study characterizes the antibody profiles and serum neutralizing capacity as well as its relationship with disease severity among COVID-19 patients from the Philippines, prior to the national COVID-19 vaccination rollout.</div></div><div><h3>Methods</h3><div>A total of 177 serum samples from 67 hospitalized patients with RT-PCR-confirmed COVID-19 were analyzed during the first wave of the pandemic between October 2020 to April 2021. Various antibody isotypes (IgG, IgM, and IgA) against SARS-CoV-2 S1, S2, RBD, and N proteins, as well as IgG antibodies against human ACE2, were quantified by enzyme-linked immunosorbent assay (ELISA). Serum neutralizing capacity was assessed by ACE2-RBD binding inhibition assay and pseudovirus neutralization assays. The relationship of the binding antibodies with various clinical parameters was also determined.</div></div><div><h3>Results</h3><div>IgG, IgM, and IgA antibody responses were associated with disease severity within two weeks of symptom onset. Notably, IgM responses positively correlated with elevated inflammatory markers, including ferritin and C-reactive protein, while IgM-N predicted in-hospital mortality. However, patient sera lacked neutralizing activity against the SARS-CoV-2 Wuhan strain. While the anti-ACE2 IgG antibodies were detected, their presence was not associated with disease severity or inflammatory responses.</div></div><div><h3>Conclusions</h3><div>These findings suggest that while binding antibodies are prevalent early in infection among COVID-19 patients early in the pandemic, serum neutralizing capacity remains low in the absence of vaccination. The clinical significance of detectable anit-ACE2 antibodies in COVID-19 warrants further investigation.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 2","pages":"Article 100217"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144167467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The frequency of post-COVID-19 condition and its clinical relevance after COVID-19 disease of employees in facilities of preschool childcare 学龄前托幼机构工作人员新冠肺炎后发病频次及其临床相关性

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2025-02-01 Epub Date: 2024-12-01 DOI: 10.1016/j.jcvp.2024.100201

Michelle Nina Braun , Anna Wolfschmidt , Andrea Kaifie , Ruediger Stephan Goertz

Objective

Evaluation of the rate and symptoms of Post-COVID-19 condition in employees in childcare.

Methods

A structured questionnaire collected data from two distinct collectives: Collective 1 (C1) consisted of a prospective cohort of 44 employees after COVID-19 disease, whereas Collective 2 (C2) included 222 employees who were retrospectively interviewed. The questionnaire mainly focused on symptoms and wellbeing during or after COVID-19.

Results

The main symptoms of Post-COVID-19 condition were impairment of focus, fatigue/exhaustion, reduced stamina, headache and dyspnoea. 30 % of the employees in C1 and 7.6 % of C2 suffered from a clinically relevant Post-COVID-19 condition with impairment of the general wellbeing. According to the WHO definition, a Post-COVID-19 condition was found in 56.6 % (C1) and 25.5 % (C2).

Conclusions

A Post-COVID-19 condition was a common finding in both our collectives but did not automatically cause an impairment of general wellbeing.

目的了解托儿人员新型冠状病毒感染后症状及发生率。方法采用结构化问卷收集来自两个不同群体的数据：集体1 （C1）包括44名COVID-19疾病后的员工，而集体2 （C2）包括222名回顾性访谈的员工。问卷主要关注COVID-19期间或之后的症状和健康状况。结果新冠肺炎后患者的主要症状为注意力障碍、疲劳/乏力、耐力下降、头痛和呼吸困难。C1区30%的员工和C2区7.6%的员工患有临床相关的后冠状病毒病，总体健康受损。根据世卫组织的定义，56.6% （C1型）和25.5% （C2型）的患者存在后冠状病毒感染。结论新冠肺炎后症状在我们两个集体中都很常见，但不会自动导致总体幸福感受损。

{"title":"The frequency of post-COVID-19 condition and its clinical relevance after COVID-19 disease of employees in facilities of preschool childcare","authors":"Michelle Nina Braun , Anna Wolfschmidt , Andrea Kaifie , Ruediger Stephan Goertz","doi":"10.1016/j.jcvp.2024.100201","DOIUrl":"10.1016/j.jcvp.2024.100201","url":null,"abstract":"<div><h3>Objective</h3><div>Evaluation of the rate and symptoms of Post-COVID-19 condition in employees in childcare.</div></div><div><h3>Methods</h3><div>A structured questionnaire collected data from two distinct collectives: Collective 1 (C1) consisted of a prospective cohort of 44 employees after COVID-19 disease, whereas Collective 2 (C2) included 222 employees who were retrospectively interviewed. The questionnaire mainly focused on symptoms and wellbeing during or after COVID-19.</div></div><div><h3>Results</h3><div>The main symptoms of Post-COVID-19 condition were impairment of focus, fatigue/exhaustion, reduced stamina, headache and dyspnoea. 30 % of the employees in C1 and 7.6 % of C2 suffered from a clinically relevant Post-COVID-19 condition with impairment of the general wellbeing. According to the WHO definition, a Post-COVID-19 condition was found in 56.6 % (C1) and 25.5 % (C2).</div></div><div><h3>Conclusions</h3><div>A Post-COVID-19 condition was a common finding in both our collectives but did not automatically cause an impairment of general wellbeing.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 1","pages":"Article 100201"},"PeriodicalIF":1.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143135905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of a flow cytometry-based surrogate assay (FlowSA) for the detection of SARS-CoV-2 in clinical samples 基于流式细胞术的替代检测法（FlowSA）在临床样品中检测SARS-CoV-2的评价

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2025-02-01 Epub Date: 2025-01-26 DOI: 10.1016/j.jcvp.2025.100204

Vinit Upasani , Marjolein Knoester , Daniele Pantano , Lili Gard , Jolanda M. Smit , Bernardina T.F. van der Gun , Adriana Tami , Izabela A. Rodenhuis-Zybert

Introduction

The current diagnostic methods for SARS-CoV-2 rely on quantitative RT-PCR. However, the presence of viral RNA in samples does not necessarily reflect the presence of an infectious virus. Therefore, the reliable detection of infectious SARS-CoV-2 in clinical samples is necessary to limit viral transmission.

Methods

We developed a flow cytometry-based surrogate assay (FlowSA), wherein the presence of infectious SARS-CoV-2 was detected using virus nucleocapsid-specific antibodies.

Results

We showed that FlowSA allows the detection of a wide range of viral titers of multiple SARS-CoV-2 variants. Furthermore, the assay was successfully used to detect infectious SARS-CoV-2 in nasopharyngeal swabs from SARS-CoV-2 positive individuals, including those with high Ct values. Notably, FlowSA identified the presence of infectious SARS-CoV-2 in biological specimens that scored negative for cytopathic effect (CPE) in cell culture and would otherwise be considered negative.

Conclusion

We propose that FlowSA can be adopted as an alternative to conventional CPE methods for viral diagnostics.

目前SARS-CoV-2的诊断方法主要依赖于定量RT-PCR。然而，样本中病毒RNA的存在并不一定反映感染性病毒的存在。因此，在临床样本中可靠地检测传染性SARS-CoV-2是限制病毒传播的必要条件。方法我们建立了一种基于流式细胞术的替代检测方法（FlowSA），其中使用病毒核衣壳特异性抗体检测传染性SARS-CoV-2的存在。结果FlowSA可以检测多种SARS-CoV-2变体的大范围病毒滴度。此外，该方法还成功地用于检测SARS-CoV-2阳性个体（包括Ct值高的个体）鼻咽拭子中的传染性SARS-CoV-2。值得注意的是，FlowSA在细胞培养中细胞病变效应（CPE）得分为阴性的生物标本中发现了传染性SARS-CoV-2的存在，否则将被视为阴性。结论FlowSA可作为传统CPE方法的替代方法用于病毒诊断。

{"title":"Evaluation of a flow cytometry-based surrogate assay (FlowSA) for the detection of SARS-CoV-2 in clinical samples","authors":"Vinit Upasani , Marjolein Knoester , Daniele Pantano , Lili Gard , Jolanda M. Smit , Bernardina T.F. van der Gun , Adriana Tami , Izabela A. Rodenhuis-Zybert","doi":"10.1016/j.jcvp.2025.100204","DOIUrl":"10.1016/j.jcvp.2025.100204","url":null,"abstract":"<div><h3>Introduction</h3><div>The current diagnostic methods for SARS-CoV-2 rely on quantitative RT-PCR. However, the presence of viral RNA in samples does not necessarily reflect the presence of an infectious virus. Therefore, the reliable detection of infectious SARS-CoV-2 in clinical samples is necessary to limit viral transmission.</div></div><div><h3>Methods</h3><div>We developed a flow cytometry-based surrogate assay (FlowSA), wherein the presence of infectious SARS-CoV-2 was detected using virus nucleocapsid-specific antibodies.</div></div><div><h3>Results</h3><div>We showed that FlowSA allows the detection of a wide range of viral titers of multiple SARS-CoV-2 variants. Furthermore, the assay was successfully used to detect infectious SARS-CoV-2 in nasopharyngeal swabs from SARS-CoV-2 positive individuals, including those with high Ct values. Notably, FlowSA identified the presence of infectious SARS-CoV-2 in biological specimens that scored negative for cytopathic effect (CPE) in cell culture and would otherwise be considered negative.</div></div><div><h3>Conclusion</h3><div>We propose that FlowSA can be adopted as an alternative to conventional CPE methods for viral diagnostics.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 1","pages":"Article 100204"},"PeriodicalIF":1.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143135907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of daily alcohol consumption and age over 40 years on COVID-19 vaccination antibody titers in the Delta era among hospital workers in northern Okinawa, Japan: A retrospective cohort study 日本冲绳北部三角洲时期医院工作人员每日饮酒量和40岁以上年龄对COVID-19疫苗抗体滴度的影响：一项回顾性队列研究

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2025-02-01 Epub Date: 2025-01-27 DOI: 10.1016/j.jcvp.2025.100205

Takuji Kishimoto , Daisuke Tasato , Yoshitaka Nagasawa , Akihiro Yamashiro , Hayashi Shokita

Background

Coronavirus disease 2019 (COVID-19) vaccination has demonstrated efficacy in preventing infection, mitigating disease severity, and lowering the incidence of Long COVID. To enhance vaccine effectiveness, it is not only important to develop more effective vaccines but also to clarify factors, including lifestyle, that affect the immune response. The aim of this study was to investigate the impact of lifestyle factors on COVID-19 vaccination antibody titers.

Methods

Antibody titers of 354 hospital workers who received two COVID-19 vaccination doses were measured five times for more than six months. Information on medical history, demographic characteristics, and lifestyle-related items was obtained from hospital health checkups. The outcome variable (Lower-25 %) was defined as the antibody titer value below the 25th percentile of the fifth measurement. The Cox proportional hazard survival model was used to evaluate the hazard ratio for incidence of Lower-25 % according to lifestyle-related items.

Results

The crude incidence rates per 1,000 person-days for Lower-25 % among women and men were 1.35 and 1.66, respectively. The hazard ratios for Lower-25 % of those in their 40 s, 50 s, and 60 s compared with those in their 20 s were 5.82 (95 % confidence interval [CI], 2.05–16.51), 7.12 (95 % CI, 2.46–20.63), and 9.96 (95 % CI, 3.07–32.34), respectively. The hazard ratios for “daily” versus “never” drinking habits were 2.26 (95 % CI 1.17–4.34).

Conclusions

The results of this study indicate that shortening vaccination intervals for individuals over 40 years and discontinuing daily alcohol consumption are associated with the preservation of acquired antibody titers for optimizing vaccine efficacy.

背景2019冠状病毒病（COVID-19）疫苗接种已被证明在预防感染、减轻疾病严重程度和降低长COVID发病率方面具有疗效。为了提高疫苗的有效性，不仅要开发更有效的疫苗，而且要弄清影响免疫反应的因素，包括生活方式。本研究的目的是探讨生活方式因素对COVID-19疫苗抗体滴度的影响。方法对354名接受2剂新冠肺炎疫苗接种的医护人员进行5次抗体滴度检测，持续6个月以上。从医院健康检查中获得了病史、人口统计学特征和生活方式相关项目的信息。结果变量（低- 25%）定义为抗体滴度值低于第五次测定的第25百分位数。根据生活方式相关项目，采用Cox比例风险生存模型评估低- 25%发生率的风险比。结果低25%人群中，女性和男性的粗发病率分别为1.35和1.66。40多岁、50多岁和60多岁的低25%患者与20多岁患者的风险比分别为5.82（95%可信区间[CI]， 2.05 ~ 16.51）、7.12 （95% CI, 2.46 ~ 20.63）和9.96 （95% CI, 3.07 ~ 32.34）。“每日”饮酒习惯与“从不”饮酒习惯的风险比为2.26 （95% CI 1.17-4.34）。结论缩短40岁以上人群的疫苗接种间隔和停止每日饮酒与保存获得性抗体滴度有关，从而优化疫苗效力。

{"title":"Effect of daily alcohol consumption and age over 40 years on COVID-19 vaccination antibody titers in the Delta era among hospital workers in northern Okinawa, Japan: A retrospective cohort study","authors":"Takuji Kishimoto , Daisuke Tasato , Yoshitaka Nagasawa , Akihiro Yamashiro , Hayashi Shokita","doi":"10.1016/j.jcvp.2025.100205","DOIUrl":"10.1016/j.jcvp.2025.100205","url":null,"abstract":"<div><h3>Background</h3><div>Coronavirus disease 2019 (COVID-19) vaccination has demonstrated efficacy in preventing infection, mitigating disease severity, and lowering the incidence of Long COVID. To enhance vaccine effectiveness, it is not only important to develop more effective vaccines but also to clarify factors, including lifestyle, that affect the immune response. The aim of this study was to investigate the impact of lifestyle factors on COVID-19 vaccination antibody titers.</div></div><div><h3>Methods</h3><div>Antibody titers of 354 hospital workers who received two COVID-19 vaccination doses were measured five times for more than six months. Information on medical history, demographic characteristics, and lifestyle-related items was obtained from hospital health checkups. The outcome variable (Lower-25 %) was defined as the antibody titer value below the 25th percentile of the fifth measurement. The Cox proportional hazard survival model was used to evaluate the hazard ratio for incidence of Lower-25 % according to lifestyle-related items.</div></div><div><h3>Results</h3><div>The crude incidence rates per 1,000 person-days for Lower-25 % among women and men were 1.35 and 1.66, respectively. The hazard ratios for Lower-25 % of those in their 40 s, 50 s, and 60 s compared with those in their 20 s were 5.82 (95 % confidence interval [CI], 2.05–16.51), 7.12 (95 % CI, 2.46–20.63), and 9.96 (95 % CI, 3.07–32.34), respectively. The hazard ratios for “daily” versus “never” drinking habits were 2.26 (95 % CI 1.17–4.34).</div></div><div><h3>Conclusions</h3><div>The results of this study indicate that shortening vaccination intervals for individuals over 40 years and discontinuing daily alcohol consumption are associated with the preservation of acquired antibody titers for optimizing vaccine efficacy.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 1","pages":"Article 100205"},"PeriodicalIF":1.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143135904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0